PD40-11 THE ROLE OF 68GA-PSMA PET-CT IN INITIAL STAGING OF TREATMENT-NAïVE HIGH RISK PROSTATE CANCER. (2019)

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy I (PD40)1 Apr 2019PD40-11 THE ROLE OF 68GA-PSMA PET-CT IN INITIAL STAGING OF TREATMENT-NAïVE HIGH RISK PROSTATE CANCER. Aydin Pooli*, Taylor Y. Sadun, David C. Johnson, Cedric Lebacle, Wolfgang P. Fendler, Matthias Eiber, Johannes Czernin, Jeremie Calais, and Robert E. Reiter Aydin Pooli*Aydin Pooli* More articles by this author , Taylor Y. SadunTaylor Y. Sadun More articles by this author , David C. JohnsonDavid C. Johnson More articles by this author , Cedric LebacleCedric Lebacle More articles by this author , Wolfgang P. FendlerWolfgang P. Fendler More articles by this author , Matthias EiberMatthias Eiber More articles by this author , Johannes CzerninJohannes Czernin More articles by this author , Jeremie CalaisJeremie Calais More articles by this author , and Robert E. ReiterRobert E. Reiter More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000556543.86104.2aAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: 68Ga-PSMA PET/CT imaging is a valuable tool for localizing biochemical recurrence of prostate cancer (PCa) after definitive treatment. We investigate the concordance of PSMA PET/CT findings with conventional imaging (CI) in initial staging of treatment-naive high-risk PCa. METHODS: We used a prospective, single institution database of patients undergoing PSMA PET/ CT from 2016-2018 (NCT03368547). All patients with high-risk PCa (n=112) and available prior CI data (n=83) were included. Patients with any treatment prior to PSMA PET/CT were excluded (n=11). We extracted clinico-pathological data, including age, initial PSA, Gleason score at biopsy, and imaging findings. We compared performance of PSMA PET/CT to CI for identifying pelvic lymph node (PLN), extra-pelvic lymph node (EPLN), bone (BM) and visceral metastasis (VM). RESULTS: A total of 72 patients with treatment-naive high-risk PCa met inclusion criteria. The mean age at presentation was 65 (44-82) and the median PSA was 42 ng/ml (2.4-155). PSMA results were discordant with CI in 15/72 (20.8%) patients. PSMA detected 12 new findings (16.7%) in nine patients with negative CI (eight positive PLNs, two positive EPLN and two BM) and ruled out suspected BM in 6/72 (8.3%) patients. CONCLUSIONS: PSMA PET/CT imaging may serve as a valuable tool in the initial staging of treatment-naive high-risk PCa. Judicious use of PSMA PET/CT can detect lymph nodes or bone metastasis missed by CI and confirm or rule out metastasis in equivocal lesions detected by CI. Source of Funding: none Los Angeles, CA; Paris, France; Los Angeles, CA© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e742-e742 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Aydin Pooli* More articles by this author Taylor Y. Sadun More articles by this author David C. Johnson More articles by this author Cedric Lebacle More articles by this author Wolfgang P. Fendler More articles by this author Matthias Eiber More articles by this author Johannes Czernin More articles by this author Jeremie Calais More articles by this author Robert E. Reiter More articles by this author Expand All Advertisement PDF downloadLoading ...